drugset / Trial / NCT07358130
Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
(1) To compare the efficacy and safety of a 14-day bismuth-amoxicillin-vonoprazan triple therapy versus a 14-day bismuth-based quadruple therapy as first-line treatments for H. pylori infection, and (2) To investigate the influence of H. pylori antibiotic resistance, along with host CYP3A4, CYP2C19, and IL-1B -511 genotypes, on the eradication efficacy of H. pylori therapies.
Timeline
- Start
- 2025-10-21
- Primary completion
- 2027-11-15
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Amoxicillin | Other / unclassified | 750 mg | — |
| Comparator | Metronidazole | Small molecule | 250 mg | — |
| Comparator | Rabeprazole | Small molecule | 20 mg | — |
| Comparator | Tetracycline | Unknown | 500 mg | — |
| Comparator | Vonoprazan | Other / unclassified | 20 mg | — |
| Comparator | tripotassium dicitrate bismuthate | Unknown | 300 mg | — |